Boston Scientific CorpAugust 25 cyberattack disrupted manufacturing and shipping, making it unlikely to meet Q3 and full-year 2026 guidance.

Boston Scientific Corporation disclosed that an August 25 cyberattack disrupted manufacturing and shipping, making it unlikely to meet its previously issued third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share. The company said operations have since resumed, but the incident is still expected to weigh on third-quarter and full-year results. The disruption did not stem from a product-quality problem; the lost sales were orders that could not ship, and distribution is already back online. Farapulse, Boston Scientific's pulsed-field-ablation system, still commands a major share of the US atrial-fibrillation market, though the company had already projected flat global electrophysiology growth for the second half of 2026 after lowering its market-share assumptions. Hedge fund holdings in BSX slipped to 99 in the second quarter of 2026 from 106 in the prior quarter, while short interest remains low at 1.9% of the float.
Boston Scientific CorpAugust 25 cyberattack disrupted manufacturing and shipping, making it unlikely to meet Q3 and full-year 2026 guidance.
PayPal Holdings Inc
Spyre Therapeutics Inc.